JP2023536086A5 - - Google Patents

Info

Publication number
JP2023536086A5
JP2023536086A5 JP2023505707A JP2023505707A JP2023536086A5 JP 2023536086 A5 JP2023536086 A5 JP 2023536086A5 JP 2023505707 A JP2023505707 A JP 2023505707A JP 2023505707 A JP2023505707 A JP 2023505707A JP 2023536086 A5 JP2023536086 A5 JP 2023536086A5
Authority
JP
Japan
Prior art keywords
cancer
bispecific molecule
ctla
use according
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023505707A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023536086A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/042901 external-priority patent/WO2022026306A1/en
Publication of JP2023536086A publication Critical patent/JP2023536086A/ja
Publication of JP2023536086A5 publication Critical patent/JP2023536086A5/ja
Pending legal-status Critical Current

Links

JP2023505707A 2020-07-27 2021-07-23 Pd‐1×ctla‐4二重特異性分子の使用のための方法 Pending JP2023536086A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063057054P 2020-07-27 2020-07-27
US63/057,054 2020-07-27
US202163177036P 2021-04-20 2021-04-20
US63/177,036 2021-04-20
US202163219066P 2021-07-07 2021-07-07
US63/219,066 2021-07-07
PCT/US2021/042901 WO2022026306A1 (en) 2020-07-27 2021-07-23 Methods for the use of a pd-1 x ctla-4 bispecific molecule

Publications (2)

Publication Number Publication Date
JP2023536086A JP2023536086A (ja) 2023-08-23
JP2023536086A5 true JP2023536086A5 (cg-RX-API-DMAC7.html) 2024-07-29

Family

ID=80036053

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023505707A Pending JP2023536086A (ja) 2020-07-27 2021-07-23 Pd‐1×ctla‐4二重特異性分子の使用のための方法

Country Status (13)

Country Link
US (1) US20230312756A1 (cg-RX-API-DMAC7.html)
EP (1) EP4188961A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023536086A (cg-RX-API-DMAC7.html)
KR (1) KR20230042038A (cg-RX-API-DMAC7.html)
CN (1) CN116134053A (cg-RX-API-DMAC7.html)
AU (1) AU2021316192A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023001487A2 (cg-RX-API-DMAC7.html)
CA (1) CA3189926A1 (cg-RX-API-DMAC7.html)
IL (1) IL300166A (cg-RX-API-DMAC7.html)
MX (1) MX2023001111A (cg-RX-API-DMAC7.html)
TW (1) TW202220691A (cg-RX-API-DMAC7.html)
WO (1) WO2022026306A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202300822B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120648657A (zh) * 2024-03-08 2025-09-16 上海锦斯生物技术有限公司 一种修饰的溶瘤病毒及其组合物
WO2026021409A1 (zh) * 2024-07-22 2026-01-29 宜明昂科生物医药技术(上海)股份有限公司 靶向ctla-4、pd-l1和vegf的肿瘤联合疗法
WO2026067794A1 (en) * 2024-09-30 2026-04-02 Shen Shi Pharmaceuticals (Shanghai) Co., Ltd. Trispecific antibodies and uses thereof
WO2026117666A1 (en) * 2024-11-26 2026-06-04 Dana-Farber Cancer Institute, Inc. Bispecific antibodies for treating cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3530736A3 (en) * 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
US9856320B2 (en) * 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
PE20231958A1 (es) * 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
CN108367069B (zh) * 2015-12-14 2022-08-23 宏观基因有限公司 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
US20190241658A1 (en) * 2016-01-10 2019-08-08 Modernatx, Inc. Therapeutic mRNAs encoding anti CTLA-4 antibodies
IL321475A (en) * 2016-05-06 2025-08-01 Medimmune Llc Bispecific binding proteins and their uses
CA3026151A1 (en) * 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
WO2018014260A1 (en) * 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
CN106967172B (zh) * 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
WO2019179421A1 (en) * 2018-03-19 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific pd-1/ctla-4 antibody molecules
US20210079094A1 (en) * 2019-03-29 2021-03-18 Xencor, Inc. Dosing of a bispecific antibody that binds pd1 and ctla4

Similar Documents

Publication Publication Date Title
US11584801B2 (en) Anti-5T4 antibodies and antibody-drug conjugates
ES2985352T3 (es) Anticuerpos para radionúclidos quelados
JP2023507848A5 (cg-RX-API-DMAC7.html)
JP2020520370A5 (cg-RX-API-DMAC7.html)
JP2009541492A5 (cg-RX-API-DMAC7.html)
JP2023519254A5 (cg-RX-API-DMAC7.html)
JP2023509323A5 (cg-RX-API-DMAC7.html)
WO2020023702A1 (en) Novel il-21 prodrugs and methods of use thereof
JP2020501531A5 (cg-RX-API-DMAC7.html)
JP2022058802A5 (cg-RX-API-DMAC7.html)
JP2010531140A5 (cg-RX-API-DMAC7.html)
JP2012509259A5 (cg-RX-API-DMAC7.html)
JP2020502271A5 (cg-RX-API-DMAC7.html)
JP2019509055A5 (cg-RX-API-DMAC7.html)
JP2017507900A5 (cg-RX-API-DMAC7.html)
WO2019195408A1 (en) Antibody variable domains targeting dll3, and use thereof
TW201902514A (zh) Pd-1抗體與vegf配體或vegf受體抑制劑聯合在製備治療腫瘤的藥物中的用途
US12391764B2 (en) Anti-CD30 and anti-CD3 bispecific antibodies and methods of immunotherapy for CD30+ malignancies
IL272770B1 (en) CD40 agonist antibodies
JP2021520201A5 (cg-RX-API-DMAC7.html)
JP2026501802A (ja) 抗egfr/muc1抗体及びその使用
JP2023549316A5 (cg-RX-API-DMAC7.html)
JP2021521245A (ja) キレート化された放射性核種に対する抗体および除去剤
JP2023525320A5 (cg-RX-API-DMAC7.html)
JP2023519807A5 (cg-RX-API-DMAC7.html)